NEW YORK, May 30 (Reuters) - Schering-Plough Corp's drug Caelyx delayed progression of symptoms among patients with advanced ovarian cancer in a late-stage study, compared with standard treatment, and ...
Final two opinions on medicines made at Ben Venue Laboratories The European Medicines Agency has recommended that the manufacturing processes for the anticancer medicines Caelyx (doxorubicin ...
The U.K. drug price watchdog today gave Johnson & Johnson's ($JNJ) Caelyx the distinction of being one of only two drugs it believes should be funded by the National ...
Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer. Seventy-one patients with stage IV breast cancer were treated with Caelyx at doses of 45 to 60 mg/m2 every 3 ...
Liposomal encapsulation of anticancer drugs has been pursued intensively during the past number of years. This pharmaceutical strategy offers the theoretical advantage of increasing drug efficiency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results